There is still a role for first generation antiandrogens (FGAs) in the management of metastatic castration-resistant prostate cancer (mCRPC), according to an Australian study. Importantly, the use of agents such as bicalutamide does not impact the efficacy of subsequent systemic therapies while a PSA50 response to FGA treatment is a significant favourable prognostic marker. The ...
First generation antiandrogens still have role in prostate cancer: real world data
By Mardi Chapman
14 Oct 2021